| ID | 1110 |
| Name of the vaccine | Plague vaccine USP |
| Microbe | Bacteria |
| Disease name | Plague |
| Name of bacteria | Yersinia pestis |
| Type of vaccine | Inactivated |
| Nucleic acid content | Circular DNA |
| Age | NA |
| Description of the vaccine | Killed whole cell vaccine for preventing bubonic plague. |
| Name of the manufacturer | Cutter Biological Inc |
| Name of the manufacturing country | United States |
| Year of manufacture | NA |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | NA |
| Mechanism of action | NA |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Malaise, headaches elevated temperature and lymphadenopathy. |
| Post vaccination | NA |
| Dose type | NA |
| Interspecies transfer | Yes (enzootic from wild rodents and their fleas) |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=31&keywords= |
| Other name | NA |
| Additional Links | https://www.tandfonline.com/doi/pdf/10.4161/hv.9866
|